Showing 4931-4940 of 5771 results for "".
- Regenxbio Exercises Option for Global License for Use of SCS Microinjector in AAV Gene Therapy Deliveryhttps://modernod.com/news/regenxbio-exercises-option-for-global-license-for-use-of-scs-microinjector-in-aav-gene-therapy-delivery/2477053/Clearside Biomedical announced that Regenxbio has exercised its option under the previously announced option and license agreement to license Clearside’s proprietary, in-office SCS Microinjector for the delivery of adeno-associated virus (AAV)-based therapeutics, including but not
- FDA Accepts Genentech’s Biologics License Application for Satralizumab for Neuromyelitis Optica Spectrum Disorderhttps://modernod.com/news/fda-accepts-genentechs-biologics-license-application-for-satralizumab-for-neuromyelitis-optica-spectrum-disorder/2477055/Genentech announced the FDA has accepted the company’s biologics license application (BLA) for satralizumab for the treatment of adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD). The European Medicines Agency (EMA) has also validated the company’s Marketing Authorization
- Eyenovia Advances MicroLine for the Treatment of Presbyopia; Reprioritizes Late-Stage Ophthalmology Pipelinehttps://modernod.com/news/eyenovia-advances-microline-for-the-treatment-of-presbyopia-reprioritizes-late-stage-ophthalmology-pipeline/2477052/Eyenovia announced that the company is advancing the development of its MicroLine program for the improvement in near vision in patients with presbyopia toward phase 3 development. As a result of prioritizing MicroLine in tandem with its MicroPine (progressive myopia) and MicroSta
- Iveric bio Appoints Abraham Scaria, PhD, as Chief Scientific Officerhttps://modernod.com/news/iveric-bio-appoints-abraham-scaria-phd-as-chief-scientific-officer/2477050/Iveric bio announced the appointment of Abraham Scaria, PhD, to the position of Chief Scientific Officer, effective October 29, 2019. Dr. Scaria will lead the company’s research and preclinical gene therapy activities. Dr. Scaria’s extensive experience includes positions at Genzyme, Sanofi, and m
- Tangible Hydra-PEG Now Available on More Gas Permeable Contact Lenshttps://modernod.com/news/tangible-hydra-peg-now-available-on-more-gas-permeable-contact-lens/2477047/Tangible Science announced that gas permeable (GP) contact lens materials from Acuity Polymers, Bausch + Lomb, Contamac, Paragon, and SynergEyes are now available for coating with Tangible Hydra-PEG. This expanded list of approved GP lens materials compatible with Tangible Hydra-PEG means that vi
- NovaBay Pharmaceuticals to Distribute the NuLids System for the Treatment of Dry Eye in Certain U.S. Geographieshttps://modernod.com/news/novabay-pharmaceuticals-to-distribute-the-nulids-system-for-the-treatment-of-dry-eye-in-certain-u-s-geographies/2477048/NovaBay Pharmaceuticals announced an exclusive 90-day agreement with NuSight Medical to distribute the NuLids System for treatment of blepharitis and dry eye in six of NovaBay’s top-performing territories. The NuLids System is a hand-held, cordless device that safely and effectively removes accum
- Iveric bio’s Zimura Meets its Primary Endpoint in a Phase 2b Trial in Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/iveric-bios-zimura-meets-its-primary-endpoint-in-a-phase-2b-trial-in-geographic-atrophy-secondary-to-dry-amd/2477046/Iveric bio announced initial topline data confirming that Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, met its prespecified primary endpoint in reducing the rate of geographic atrophy (GA) growth in patients with dry age-related macular degeneration (AMD) in a random
- Lineage Cell Therapeutics Presents Encouraging Data on Vision Restoration Programhttps://modernod.com/news/lineage-cell-therapeutics-presents-encouraging-data-on-vision-restoration-program/2477041/Lineage Cell Therapeutics announced today that Igor Nasonkin, PhD, Principal Investigator and Director of R&D, served as a co-Chair of the Neural Differentiation, Transplantation, and Regeneration Nanosymposium, in addition to presenting data on the company’s Vision Restoration Program at Neu
- Adverum Biotechnologies Doses First Patient in Third Cohort of OPTIC Clinical Trial of Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-doses-first-patient-in-third-cohort-of-optic-phase-1-clinical-trial-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2477039/Adverum Biotechnologies announced that the first patient was dosed in the third cohort (n=9) of the ongoing OPTIC phase 1 clinical trial for ADVM-022 for the treatment of neovascular age-related macular degeneration (AMD). Patients in this cohort are receiving a single intravitreal injection of g
- SightGlass Vision to Present New Data on its Novel Lenses to Control Nearsightedness in Children at 3rd World Congress of Optometryhttps://modernod.com/news/sightglass-vision-to-present-new-data-on-its-novel-lenses-to-control-nearsightedness-in-children-at-3rd-world-congress-of-optometry/2477040/SightGlass Vision announced that data from three clinical trials overviewing discovery to clinical development of its novel spectacle lenses will be presented for the first time in a scientific forum at the 3rd World Congress of Optometry (WCO19) and Academy 2019 (Academy19), held